CEO Witty's 2017 Exit Could Hasten Glaxo's Consumer Business Decision

Glaxo CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change. His biggest legacy could be the multi-asset swap he orchestrated with Novartis in 2014 that created a consumer health care JV with the Swiss firm.